MediWound's EscharEx Program Bolstered by €16.25 Million Funding from European Innovation Council
Tuesday, 16 July 2024, 13:46
MediWound Secures €16.25 Million Funding
MediWound, a leading healthcare company, has received a significant boost with a funding injection of €16.25 million from the European Innovation Council.
Advancing EscharEx Development Program
- Objective: Further advancement in treating diabetic foot ulcers.
- Significance: Accelerating research and development efforts.
- Impact: Potential advancements in diabetic wound care.
This funding positions MediWound to make significant strides in combating a prevalent healthcare concern.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.